Resveratrol is found in numerous plant-based foods and beverages and is known to have an impact on the cardiovascular system. The aim of this study was to investigate the vasorelaxant effect of resveratrol and its underlying mechanisms by employing an aortic ring assay model. Resveratrol caused relaxation of aortic rings that had been precontracted with phenylephrine in the presence of endothelium or with potassium chloride in endothelium-intact aortic rings. The vasorelaxant effect was decreased in the absence of an endothelium. The mechanisms underlying the vasorelaxant effect of resveratrol were determined through the addition of antagonists. In the presence of the endothelium, indomethacin (a nonselective cyclooxygenase inhibitor), methylene blue (cyclic guanosine monophosphate lowering agent), 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, selective soluble guanylate cyclase inhibitor), Nω-nitro-l-arginine methyl ester (L-NAME, nitric oxide synthase inhibitor), tetraethylammonium (TEA, nonselective calcium activator potassium channel blocker), 4-aminopyridine (4-AP, voltage-dependent K+ channel blocker), barium chloride (BaCl2, inwardly rectifying K+ channel blocker), glibenclamide (non-specific ATP-sensitive K+ channel blocker) and propranolol (β-adrenergic receptor blocker) led to a significant reduction in the vasorelaxation effect induced by resveratrol. Resveratrol was also found to reduce Ca2+ release from the sarcoplasmic reticulum and block calcium channels. In conclusion, resveratrol targets multiple signalling pathways for exerting its vasorelaxant effects in the rat aortic ring model in both the presence and absence of endothelium.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Aubin MC, Lajoie C, Clement R, Gosselin H, Calderone A, Perrault LP (2008) Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther 325:961–968
Bastinetto S, Menard C, Quirion R (2015) Neuroprotective action of resveratrol. Biochem Biophys Acta 1852:1195–1201
Buluc M, Emine Demirel-Yilmaz E (2006) Resveratrol decreases calcium sensitivity of vascular smooth muscle and enhances cytosolic calcium increase in endothelium. Vascul Pharmacol 44:231–237
Chan V, Fenning A, Iyer A, Hoey A, Brown L (2011) Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr Pharm Biotechnol 12:429–436
Diaz M, Degan H, Vanhees L, Austin C, Azzawi M (2016) The effects of resveratrol on aging vessels. Exp Gerontol 85:41–47
Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, Zordoky BN, Morton JS, Nagendran J, Lopaschuk GD, Davidge ST, Dyck JR (2013) Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta 1832:1723–1733
Gresele P, Cerletti C, Guglielmini G, Pignatelli P, de Gaetano G, Violim F (2011) Effect of resveratrol and other wine polyphenols on vascular function: an update. J Nutr Biochem 22:201–211
Hamza SM, Dyck JRB (2014) Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol. Front Physiol 5:292
Iwamuro Y, Miwa S, Minowa T, Enoki T, Zhang X, Ishikawa M, Hashimoto N, Masaki T (1998) Activation of two types of Ca2+-permeable nonselective cation channel by endothelin-1 in A7r5 cells. Br J Pharmacol 124(7):1541–1549
Jakala P, Pere E, Lehtinen R, Turpeinen A, Korpela R, Vapaatalo H (2009) Cardiovascular activity of milk casein-derived tripeptides and plant sterols in spontaneously hypertensive rats. J Physiol Pharmacol 60(4):11–20
Li HF, Chen SA, Wu SN (2000) Evidence for the stimulatory effect of resveratrol on Ca(2+)-activated K+ current in vascular endothelial cells. Cardiovass Res. 45(4):1035–1045
Liu Z, Song Y, Zhang X, Zhang W, Mao W, Wang W, Cui W, Jia X, Li N, Han C, Liu C (2005) Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharmacol Physiol 32:1049–1054
Loh YC, Tan CS, Ch’ng YS, Ahmad M, Asmawi MZ, Yam MF (2016) Overview of antagonists used for determining the mechanisms of action employed by potential vasodilators with their suggested signaling pathways. Molecules 21(4):495
Loh YC, Tan CS, Ch’ng YS, Yeap ZQ, Ng CH, Yam MF (2018) Overview of the microenvironment of vasculature in vascular tone regulation. Int J Mol Sci 19:120
Naderali EK (2009) Obesity and cardiovascular dysfunction: a role for resveratrol? Obes Res Clin Pract 3:45–52
Naderali EK, Smith SL, Doyle PJ, Williams G (2001) The mechanism of resveratrol-induced vasorelaxation differs in the mesenteric resistance arteries of lean and obese rats. Clin Sci 100:55–60
Putney JW (2010) Pharmacology of store-operated calcium channels. Mol Interventions 10(4):209–218
Rakici O, Kiziltepe U, Coskun B, Aslamaci S, Akar F (2005) Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int J Cardiol 105:209–215
Senejoux F, Demougeot C, Cuciureanu M, Miron A, Cuciureanu R, Berthelot A, Girard-Thernier C (2013) Vasorelaxation effects and mechanisms of action of Heracleums phondylium L. (Apiaceae) in rat thoracic aorta. J Ethnopharmacol 147(2):536–539
Shen M, Zhao L, Wu R, Yue S, Pei J (2013) The vasorelaxing effect of resveratrol on abdominal aorta from rats and its underlying mechanisms. Vascul Pharmacol 58:64–70
Subramanian M, Balasubramanian P, Garver H, Northcott C, Zhao H, Haywood JR, Fink GD, MohanKumar SM, MohanKumar PS (2011) Chronic estradiol-17 beta exposure increases superoxide production in the rostral ventrolateral medulla and causes hypertension: reversal by resveratrol. Am J Physiol Regul Integr Comp Physiol 300:1560–1568
Tan CS, Yam MF (2018) Mechanism of vasorelaxation induced by 3′-hydroxy-5,6,7,4′-tetramethoxyflavone in the rats aortic ring assay. Naunyn-Schmiedeberg’s Arch Pharmacol 391(6):561–569
Tan CS, Ch’ng YS, Loh YC, Asmawi MZ, Ahmad M, Yam MF (2017) Vasorelaxation effect of Glycyrrhizae uralensis through the endothelium-dependent pathway. J Ethnopharmacol 199:149–160
Tan CS, Loh YC, Ng CH, Ch’ng YS, Asmawi MZ, Ahmad M, Yam MF (2018) Anti-hypertensive and vasodilatory effects of amended Banxia Baizhu Tianma Tang. Biomed Pharmacother 97:985–994
Tan CS, Loh YC, Ch’ng YS, Ng CH, Yeap ZQ, Ahmad M, Asmawi MZ, Yam MF (2019) Vasorelaxant and chemical fingerprint studies of Citrus reticulatae pericarpium extracts. J. Ethnopharmacology 232:135–144
Toklu HZ, Sehirli O, Ersahin M, Suleymanoglu S, Yiginer O, Emekli-Alturfan E, Yarat A, Yegen BC, Sener G (2010) Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats. J Pharm Pharmacol 62(12):1784–1793
Wong SL, Wong WT, Tian XY, Lau CW, Huang Y (2010) Prostaglandins in action: indispensable roles of c yclooxgenase-1 and -2 in endothelium-dependent contractions. Adv Pharmacol 60:61–83
Yam MF, Tan CS, Ahmad Mariam, Ruan S (2016) Mechanism of vasorelaxation induced by eupatorin in the rats aortic ring. Eur J Pharmacol 789:27–36
Yildiz O, Gul H, Seyrek M (2013) Pharmacology of arterial grafts for coronary artery bypass surgery. INTECH Open Access Publisher, Newyork
Zordoky BNM, Robertson IM, Dyck JRB (2015) Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochem Biophys Acta 1852:1155–1177
The author would like to express deepest appreciation to all the authors who made contributions to this research. This project was supported by Fundamental Research Grant Scheme (FRGS) (203/PFARMASI/6711306), Exploratory Research Grant Scheme (ERGS) (203/PFARMASI/6730122) and Universiti Sains Malaysia-Research University Grants (1001/PFARMASI/812195).
Conflict of interest
We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. The authors declare no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Tan, C.S., Loh, Y.C., Tew, W.Y. et al. Vasorelaxant effect of 3,5,4′-trihydroxy-trans-stilbene (resveratrol) and its underlying mechanism. Inflammopharmacol (2020). https://doi.org/10.1007/s10787-019-00682-6
- Vasorelaxant activity
- Aortic ring assay
- Potassium and Calcium channels